Уважаемая Анна,
Не знаю фирменных названий, но по силе действия они немного различаются
granisetron > ondansetron > dolasetron
Многое зависит какую все-таки терапию получала пациентка и в какой дозе - разная противорвотная эффективность:
Complete response and total control rates seen with specific drugs range from 60%–80% for moderately emetogenic chemotherapy, 40%–60% for cisplatin-containing therapy, and 25%–60% for high-dose cisplatin regimens.
Также вопрос адекватности дозы:
However, due to cost considerations, many of these agents are often used at lower than optimal doses. In the U.S., the approved dose of intravenous ondansetron is 32 mg; however, ondansetron is frequently given at doses as low as 8 mg when administered as part of a combination treatment approach for moderately or highly emetogenic chemotherapy. The impact of such a practice on symptom control may jeopardize effective patient management. In contrast, oral dolasetron is approved in the U.S. for use with moderately emetogenic chemotherapy at a dose of 100 mg administered within 1 hour before chemotherapy. However, a dose-related response for oral dolasetron has been shown to occur at doses between 25 and 200 mg. Indeed, a significant linear dose-response relationship was observed in 399 cancer patients receiving moderately emetogenic chemotherapy over the entire dolasetron dose range of 25–200 mg (p < 0.001), with complete response rates of 60.5% and 76.3% achieved with the 100 mg and 200 mg doses, respectivelу.
Consideration of the consequences of potentially worse acute control, with its associated adverse clinical, humanistic, and economic effects, is therefore essential before administering lower-than-indicated doses of any approved agent. Administration of lower doses of agents with lower potency and/or shorter half-lives in those patients receiving carboplatin or cyclophosphamide agents (in whom nausea and vomiting typically peak about 12–18 hours after administration) may be particularly detrimental.
|